<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37524516</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Frailty and emergency department utilisation in adults with systemic lupus erythematosus &#x2264;65 years of age: an administrative claims data analysis of Medicaid beneficiaries.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000905</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000905</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Frailty is a risk factor for adverse health in adults with SLE, including those &lt;65 years. Emergency department (ED) utilisation is high in adults with SLE, but to our knowledge, whether frailty is associated with ED use is unknown. In a large administrative claims dataset, we assessed risk of ED utilisation among frail adults with SLE &#x2264;65 years of age relative to non-frail adults &#x2264;65 years of age with SLE.</AbstractText><AbstractText Label="METHODS">Using the MarketScan Medicaid subset from 2011 to 2015, we identified beneficiaries 18-65 years with SLE (&#x2265;3 SLE International Classification of Diseases, Ninth Revision codes &#x2265;30 days apart). Comparators without a systemic rheumatic disease (SRD) were matched 4:1 on age and gender. Frailty status in 2011 was determined using two claims-based frailty indices (CFIs). We compared risk of recurrent ED utilisation among frail and non-frail beneficiaries with SLE using an extension of the Cox proportional hazard model for recurrent events data.</AbstractText><AbstractText Label="RESULTS">Of 2262 beneficiaries with SLE and 9048 non-SRD comparators, 28.8% and 11.6% were frail, respectively, according to both CFIs. Compared with non-frail beneficiaries with SLE, frail beneficiaries with SLE had significantly higher hazard of recurrent ED use (HR 1.75, 95% CI 1.48 to 2.08).</AbstractText><AbstractText Label="CONCLUSION">Frailty increased hazard of recurrent ED visits in frail adults &#x2264;65 years of age with SLE relative to comparable non-frail adults with SLE. Frailty is a potential target for efforts to improve quality of care in SLE.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lieber</LastName><ForeName>Sarah B</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0000-0002-6176-9740</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital for Special Surgery, New York City, New York, USA LieberS@hss.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine, Weill Cornell Medicine, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nahid</LastName><ForeName>Musarrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine, Division of General Internal Medicine, Weill Cornell Medicine, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro-Mill&#xe1;n</LastName><ForeName>Iris</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-9540-6614</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital for Special Surgery, New York City, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine, Division of General Internal Medicine, Weill Cornell Medicine, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajan</LastName><ForeName>Mangala</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medicine, Division of General Internal Medicine, Weill Cornell Medicine, New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sattui</LastName><ForeName>Sebastian E</ForeName><Initials>SE</Initials><Identifier Source="ORCID">0000-0002-3945-6828</Identifier><AffiliationInfo><Affiliation>Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandl</LastName><ForeName>Lisa A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Hospital for Special Surgery, New York City, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine, Weill Cornell Medicine, New York City, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 AR072583</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 TR002385</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073496" MajorTopicYN="Y">Frailty</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008484" MajorTopicYN="N">Medicaid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078332" MajorTopicYN="N">Data Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword><Keyword MajorTopicYN="N">Outcome Assessment, Health Care</Keyword><Keyword MajorTopicYN="N">Quality Indicators, Health Care</Keyword></KeywordList><CoiStatement>Competing interests: SES discloses research support from AstraZeneca and consulting for Sanofi (funds used for research support). LAM discloses research grants from Regeneron Pharmaceuticals, royalties from UpToDate, and salary support from Annals of Internal Medicine.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>1</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>21</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37524516</ArticleId><ArticleId IdType="pmc">PMC10391790</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000905</ArticleId><ArticleId IdType="pii">10/2/e000905</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ugarte-Gil MF, Dubey J, McGwin G, et al. . Association of systemic lupus International collaborating clinics frailty index with damage in systemic lupus erythematosus patients: results from a multiethnic, multicenter US cohort of patients with lupus. Arthritis Care Res (Hoboken) 2023;75:585&#x2013;9. 10.1002/acr.24878</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24878</ArticleId><ArticleId IdType="pubmed">35255194</ArticleId></ArticleIdList></Reference><Reference><Citation>Legge A, Kirkland S, Rockwood K, et al. . Prediction of hospitalizations in systemic lupus erythematosus using the systemic lupus International collaborating clinics frailty index. Arthritis Care Res (Hoboken) 2022;74:638&#x2013;47. 10.1002/acr.24504</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24504</ArticleId><ArticleId IdType="pmc">PMC8096857</ArticleId><ArticleId IdType="pubmed">33152181</ArticleId></ArticleIdList></Reference><Reference><Citation>Legge A, Kirkland S, Rockwood K, et al. . Evaluating the properties of a frailty index and its association with mortality risk among patients with systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1297&#x2013;307. 10.1002/art.40859</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40859</ArticleId><ArticleId IdType="pmc">PMC6663648</ArticleId><ArticleId IdType="pubmed">30771242</ArticleId></ArticleIdList></Reference><Reference><Citation>Panopalis P, Gillis JZ, Yazdany J, et al. . Frequent use of the emergency department among persons with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62:401&#x2013;8. 10.1002/acr.20107</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.20107</ArticleId><ArticleId IdType="pmc">PMC3759153</ArticleId><ArticleId IdType="pubmed">20391487</ArticleId></ArticleIdList></Reference><Reference><Citation>Murimi-Worstell IB, Lin DH, Kan H, et al. . Healthcare utilization and costs of systemic lupus erythematosus by disease severity in the United States. J Rheumatol 2021;48:385&#x2013;93. 10.3899/jrheum.191187</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.191187</ArticleId><ArticleId IdType="pubmed">32611669</ArticleId></ArticleIdList></Reference><Reference><Citation>Garris C, Jhingran P, Bass D, et al. . Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 2013;16:667&#x2013;77. 10.3111/13696998.2013.778270</Citation><ArticleIdList><ArticleId IdType="doi">10.3111/13696998.2013.778270</ArticleId><ArticleId IdType="pubmed">23425294</ArticleId></ArticleIdList></Reference><Reference><Citation>Furst DE, Clarke A, Fernandes AW, et al. . Resource utilization and direct medical costs in adult systemic lupus erythematosus patients from a commercially insured population. Lupus 2013;22:268&#x2013;78. 10.1177/0961203312474087</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203312474087</ArticleId><ArticleId IdType="pubmed">23340996</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T, Carls GS, Panopalis P, et al. . Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large Medicaid population. Arthritis Rheum 2009;61:755&#x2013;63. 10.1002/art.24545</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24545</ArticleId><ArticleId IdType="pubmed">19479688</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Xu C, Williams J, et al. . Patterns and predictors of recurrent acute care use among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum 2020;50:1428&#x2013;36. 10.1016/j.semarthrit.2020.02.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.02.012</ArticleId><ArticleId IdType="pmc">PMC7483304</ArticleId><ArticleId IdType="pubmed">32252975</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbhaiya M, Feldman CH, Chen SK, et al. . Comparative risks of cardiovascular disease in patients with systemic lupus erythematosus, diabetes mellitus, and in general Medicaid recipients. Arthritis Care Res (Hoboken) 2020;72:1431&#x2013;9. 10.1002/acr.24328</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24328</ArticleId><ArticleId IdType="pmc">PMC7781242</ArticleId><ArticleId IdType="pubmed">32475049</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman ED, Klees BS, Curtis CA. Overview of the Medicare and Medicaid programs. Health Care Financ Rev 2000;22:175&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4194683</ArticleId><ArticleId IdType="pubmed">25372783</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochar B, Orkaby AR, Ananthakrishnan AN, et al. . Frailty in inflammatory bowel diseases: an emerging concept. Therap Adv Gastroenterol 2021;14:17562848211025474. 10.1177/17562848211025474</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/17562848211025474</ArticleId><ArticleId IdType="pmc">PMC8477705</ArticleId><ArticleId IdType="pubmed">34594400</ArticleId></ArticleIdList></Reference><Reference><Citation>Handforth C, Clegg A, Young C, et al. . The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091&#x2013;101. 10.1093/annonc/mdu540</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/annonc/mdu540</ArticleId><ArticleId IdType="pubmed">25403592</ArticleId></ArticleIdList></Reference><Reference><Citation>Levett TJ, Cresswell FV, Malik MA, et al. . Systematic review of prevalence and predictors of frailty in individuals with human immunodeficiency virus. J Am Geriatr Soc 2016;64:1006&#x2013;14. 10.1111/jgs.14101</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14101</ArticleId><ArticleId IdType="pubmed">27225356</ArticleId></ArticleIdList></Reference><Reference><Citation>Melo GC, Carvalho ACA, Mendes MLT, et al. . Association between frailty phenotype, quantification of plasma HIV-1 RNA, CD4 cell count and HAART in HIV-positive subjects: a systematic review and meta-analysis of observational studies. AIDS Care 2022;34:1159&#x2013;68. 10.1080/09540121.2021.1956414</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540121.2021.1956414</ArticleId><ArticleId IdType="pubmed">34292108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima G. Prevalence of frailty in end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol 2017;49:1989&#x2013;97. 10.1007/s11255-017-1547-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-017-1547-5</ArticleId><ArticleId IdType="pubmed">28229311</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery E, Macdonald PS, Newton PJ, et al. . Frailty in lung transplantation: a systematic review. Expert Rev Respir Med 2020;14:219&#x2013;27. 10.1080/17476348.2020.1702527</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17476348.2020.1702527</ArticleId><ArticleId IdType="pubmed">31815560</ArticleId></ArticleIdList></Reference><Reference><Citation>Quint EE, Zogaj D, Banning LBD, et al. . Frailty and kidney transplantation: a systematic review and meta-analysis. Transplant Direct 2021;7:e701. 10.1097/TXD.0000000000001156</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TXD.0000000000001156</ArticleId><ArticleId IdType="pmc">PMC8133203</ArticleId><ArticleId IdType="pubmed">34036171</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal JB, Chang H-Y, Du Y, et al. . Development of a claims-based frailty indicator anchored to a well-established frailty phenotype. Med Care 2017;55:716&#x2013;22. 10.1097/MLR.0000000000000729</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000729</ArticleId><ArticleId IdType="pmc">PMC5471130</ArticleId><ArticleId IdType="pubmed">28437320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandeen-Roche K, Xue Q-L, Ferrucci L, et al. . Phenotype of frailty: characterization in the women&#x2019;s health and aging studies. J Gerontol A Biol Sci Med Sci 2006;61:262&#x2013;6. 10.1093/gerona/61.3.262</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/61.3.262</ArticleId><ArticleId IdType="pubmed">16567375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Schneeweiss S, Glynn RJ, et al. . Measuring frailty in Medicare data: development and validation of a claims-based frailty index. J Gerontol A Biol Sci Med Sci 2018;73:980&#x2013;7. 10.1093/gerona/glx229</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glx229</ArticleId><ArticleId IdType="pmc">PMC6001883</ArticleId><ArticleId IdType="pubmed">29244057</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz PP, Andrews J, Yazdany J, et al. . Is Frailty a relevant concept in SLE Lupus Sci Med 2017;4:e000186. 10.1136/lupus-2016-000186</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000186</ArticleId><ArticleId IdType="pmc">PMC5294024</ArticleId><ArticleId IdType="pubmed">28243456</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieber SB, Nahid M, Paget S, et al. . Evaluation of a patient-reported frailty tool in women with systemic lupus erythematosus. J Rheumatol 2022;49:60&#x2013;7. 10.3899/jrheum.201466</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.201466</ArticleId><ArticleId IdType="pmc">PMC10279522</ArticleId><ArticleId IdType="pubmed">34470795</ArticleId></ArticleIdList></Reference><Reference><Citation>Legge A, Kirkland S, Rockwood K, et al. . Prediction of damage accrual in systemic lupus erythematosus using the systemic lupus International collaborating clinics Frailty index. Arthritis Rheumatol 2020;72:658&#x2013;66. 10.1002/art.41144</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41144</ArticleId><ArticleId IdType="pmc">PMC7113092</ArticleId><ArticleId IdType="pubmed">31631584</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima K, Legge A, Hanly JG, et al. . Association of the systemic lupus International collaborating clinics frailty index and damage accrual in long standing systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2023;75:578&#x2013;84. 10.1002/acr.24798</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24798</ArticleId><ArticleId IdType="pmc">PMC8964839</ArticleId><ArticleId IdType="pubmed">34590445</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim DH, Patorno E, Pawar A, et al. . Measuring frailty in administrative claims data: comparative performance of four claims-based frailty measures in the U.S. Medicare data. J Gerontol A Biol Sci Med Sci 2020;75:1120&#x2013;5. 10.1093/gerona/glz224</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glz224</ArticleId><ArticleId IdType="pmc">PMC7243587</ArticleId><ArticleId IdType="pubmed">31566201</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PK, Gill RD. Cox&#x2019;s regression model for counting processes: a large sample study. Ann Statist 1982;10:1100&#x2013;20. 10.1214/aos/1176345976</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/aos/1176345976</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M, Near AM, Desta B, et al. . Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015. Lupus Sci Med 2021;8:e000503. 10.1136/lupus-2021-000503</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000503</ArticleId><ArticleId IdType="pmc">PMC8442098</ArticleId><ArticleId IdType="pubmed">34521733</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012;16:601&#x2013;8. 10.1007/s12603-012-0084-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-012-0084-2</ArticleId><ArticleId IdType="pmc">PMC4515112</ArticleId><ArticleId IdType="pubmed">22836700</ArticleId></ArticleIdList></Reference><Reference><Citation>Legge A, Kirkland S, Rockwood K, et al. . Construction of a frailty index as a novel health measure in systemic lupus erythematosus. J Rheumatol 2020;47:72&#x2013;81. 10.3899/jrheum.181338</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.181338</ArticleId><ArticleId IdType="pmc">PMC6800806</ArticleId><ArticleId IdType="pubmed">30988130</ArticleId></ArticleIdList></Reference><Reference><Citation>Legge A, Malone A, Hanly JG. External validation of the systemic lupus International collaborating clinics frailty index as a predictor of adverse health outcomes in systemic lupus erythematosus. Rheumatology (Oxford) 2022;61:1919&#x2013;27. 10.1093/rheumatology/keab546</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab546</ArticleId><ArticleId IdType="pubmed">34410347</ArticleId></ArticleIdList></Reference><Reference><Citation>Elera-Fitzcarrald C, Gamboa-C&#xe1;rdenas RV, Reat&#xe9;gui-Sokolova C, et al. . The SLICC-FI predicts damage accrual in SLE patients. data from the almenara lupus cohort. Lupus 2022;31:1666&#x2013;70. 10.1177/09612033221126855</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221126855</ArticleId><ArticleId IdType="pubmed">36165429</ArticleId></ArticleIdList></Reference><Reference><Citation>Keramiotou K, Anagnostou C, Konstantonis G, et al. . SLICC-frailty index is independently associated with impaired physical function, activities of daily living, and quality of life measures. Rheumatology (Oxford) 2022;61:3808&#x2013;13. 10.1093/rheumatology/keac001</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac001</ArticleId><ArticleId IdType="pubmed">35015829</ArticleId></ArticleIdList></Reference><Reference><Citation>Dent E, Morley JE, Cruz-Jentoft AJ, et al. . Physical frailty: ICFSR International clinical practice guidelines for identification and management. J Nutr Health Aging 2019;23:771&#x2013;87. 10.1007/s12603-019-1273-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12603-019-1273-z</ArticleId><ArticleId IdType="pmc">PMC6800406</ArticleId><ArticleId IdType="pubmed">31641726</ArticleId></ArticleIdList></Reference><Reference><Citation>Kan HJ, Song X, Johnson BH, et al. . Healthcare utilization and costs of systemic lupus erythematosus in Medicaid. Biomed Res Int 2013;2013:808391. 10.1155/2013/808391</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/808391</ArticleId><ArticleId IdType="pmc">PMC3591216</ArticleId><ArticleId IdType="pubmed">23484162</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi SM, Steinberg N, Oh G, et al. . Change in a claims-based frailty index, mortality, and Healthcare costs in Medicare beneficiaries. J Gerontol A Biol Sci Med Sci 2023:glad010. 10.1093/gerona/glad010</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glad010</ArticleId><ArticleId IdType="pmc">PMC10329229</ArticleId><ArticleId IdType="pubmed">36630699</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarro-Mill&#xe1;n I, Xie F, Crowson CS, et al. . Comparing cardiovascular risk of patients with rheumatoid arthritis within the social security disability insurance with those commercially insured. Arthritis Res Ther 2022;24:202. 10.1186/s13075-022-02847-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02847-1</ArticleId><ArticleId IdType="pmc">PMC9396772</ArticleId><ArticleId IdType="pubmed">35996193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryor KP, Barbhaiya M, Costenbader KH, et al. . Disparities in lupus and lupus nephritis care and outcomes among US Medicaid beneficiaries. Rheum Dis Clin North Am 2021;47:41&#x2013;53. 10.1016/j.rdc.2020.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2020.09.004</ArticleId><ArticleId IdType="pmc">PMC8171807</ArticleId><ArticleId IdType="pubmed">34042053</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders H-J, Saxena R, Zhao M-H, et al. . Lupus nephritis. Nat Rev Dis Primers 2020;6:7. 10.1038/s41572-019-0141-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-019-0141-9</ArticleId><ArticleId IdType="pubmed">31974366</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein BA, Bhavsar NA, Phelan M, et al. . Controlling for informed presence bias due to the number of health encounters in an electronic health record. Am J Epidemiol 2016;184:847&#x2013;55. 10.1093/aje/kww112</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kww112</ArticleId><ArticleId IdType="pmc">PMC5152663</ArticleId><ArticleId IdType="pubmed">27852603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>